The global cell lysis & disruption market size was valued at USD 3.23 billion in 2018 and is projected to expand at a CAGR of 8.31% during the forecast period. This growth is attributed to the higher adoption of cell lysis and disruption methods during downstream processing to manufacture bio-therapeutics and other animal-based recombinant products.
Rise in investments by various government as well as private organizations in R&D related to biotechnological processes, and academics are expected to further drive the market significantly. In addition, rise in prevalence of various disorders and demand for novel therapeutics are expected to propel market growth.
Expansion in the biopharmaceutical industry would also provide new growth avenues to the market, as retrieval and purification of biopharmaceuticals involves cell lysis & disruption. Moreover, the adoption of biotech processes in pharmaceutical, agricultural, and bio-services industries is expected to drive the market progress as cell lysis holds substantial importance in the course of the bioprocess.
The rise in demand for efficient tumor tissue dissociation equipment has led to the development of novel products based on microfluidics. Microfluidic devices are useful in efficient dissociation of tumor tissues in single cells and thereby enhance cell recovery with respect to number and purity.
Physical disruption methods were traditionally adopted by major players operating in this space for the extraction of intracellular contents. However, the adoption of these methods has relatively decreased currently owing to the requirement for expensive and cumbersome equipment. Owing to the presence of variability in the apparatus, physical disruption methods are difficult to repeat, thus reducing their market penetration
On the contrary, reagent-based methods do not destroy the biological activity of the final products, are mild, and ideally suited for laboratory samples. The mentioned facts make them a suitable choice for laboratory usage, consequently leading to their dominance in terms of market share in 2018, and over the forecast period.
Reagents and consumables accounted for the largest share in revenue in 2018, out of which enzymes dominated the cell lysis & disruption market and are expected to grow with the faster pace in the coming years as well. Factors attributing to the estimated share include application for the selective product release, and controlled lysis as these provide biological specificity to the process. Owing to the enzyme specificity, different kits and enzymes are available for bacterial, plant, yeast, and mammalian samples. These enzymes are commercially available in a variety of forms. Major brands include but are not limited to Alfa Aesar, Millipore Sigma, MP Biochemicals LLC, Pierce Biotechnology Inc, and Promega Corporation.
The mammalian cells segment accounted for the largest share in 2018 and is expected to remain dominant throughout the forecast period. This is because mammalian culture systems are extensively used during the bio-manufacturing of viral vaccines, therapeutic proteins, and other recombinant products. In addition, the adoption of 3D mammalian culture systems in stem cell and cancer research is anticipated boost segment growth.
As the efficiency of reagents varies with the type of cell used, key companies have developed reagents that work specifically on mammalian cells. For instance, Merck Millipore provides a range of mammalian lysis reagents that are utilized for the preparation of mammalian phosphorylated, cytosolic, and nuclear proteins. Some of these products are CytoBuster protein extraction reagent, NucBuster protein extraction kit, PhosphoSafe extraction reagent, and ProteoExtract kits.
These methods find wide applications in protein isolation and downstream processing of biopharmaceuticals. The major application areas of protein isolation include proteomics, western blotting, and immunoprecipitation. Demand for the efficient and rapid lysis techniques that can extract proteins with minimal breakdown or oxidation is expected to fuel segment growth. Viscosity, which is resultant of the cell debris and genomic contamination is another challenge that needs to be addressed, pronouncing research in this segment. The development of advanced bioprocessing reagents and equipment that can readily complement the established disruption procedures are anticipated to propel growth in the market.
Academic and research institutes held the largest market share in 2018. This is due to the presence of a large number of biotechnology institutes that explore molecular biology, and bioprocess techniques, thus using cell lysis protocols.
The presence of several protocols for the tumorigenicity testing and research has led to a substantial demand for cell disruption methods in the biospecimen banking facilities. Clinical research carried out for drug development is expected to drive the growth in the years to come.
North America accounted for the largest revenue share of more than 40.0% in 2018. Various government initiatives in U.S. and Canada that support molecular biology research, precision medicine, and cancer research are expected to impel the cell lysis and disruption market growth in this region. High private, as well as public, investments in target therapeutics and novel drug discovery for the treatment various complicated and rare diseases are anticipated to drive the demand further. However, Asia Pacific is poised to witness the fastest growth over the forecast period owing to the growing interest of key companies in emerging markets to reap higher profits.
Key companies in the market include Thermo Fisher Scientific, Inc.; Merck KGaA; F. Hoffmann-La Roche Ltd; Qiagen NV; Becton Dickinson & Company (BD); Danaher Corporation; Bio-Rad Laboratories, Inc.; Miltenyi Biotec GmbH; Claremont BioSolutions, LLC; Microfluidics International Corporation; Parr Instrument Company; BioVision, Inc.; Covaris, Inc.; and Qsonica LLC. These companies focused on novel product development and acquisitions/collaborations to enhance their market position. For instance, in February 2018, Miltenyi Biotec GmbH received EMA approval for its CliniMACS Prodigy equipment - an automated device for cell production.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2025
Revenue in USD Million and CAGR from 2019 to 2025
North America, Europe, Asia Pacific, Latin America, and MEA
U.S., Canada, Germany, U.K., Japan, China, India, Brazil, Mexico, South Africa, and Saudi Arabia
Revenue forecast, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cell lysis & disruption market report on the basis of technique, product, cell type, application, end use, and region:
Technique Outlook (Revenue, USD Million, 2014 - 2025)
Product Outlook (Revenue, USD Million, 2014 - 2025)
High Pressure Homogenizers
Reagents & Consumables
Kits & Reagents
Cell Type Outlook (Revenue, USD Million, 2014 - 2025)
Application Outlook (Revenue, USD Million, 2014 - 2025)
Cell Organelle Isolation
Nucleic Acid Isolation
End Use Outlook (Revenue, USD Million, 2014 - 2025)
Academic & Research Institutes
Hospitals & Diagnostic Labs
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.